X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (36) 36
humans (35) 35
oncology (28) 28
male (27) 27
adult (23) 23
female (22) 22
middle aged (22) 22
aged (21) 21
cancer (18) 18
survival (14) 14
gastroenterology & hepatology (11) 11
hepatocellular carcinoma (11) 11
tumors (11) 11
aged, 80 and over (10) 10
management (10) 10
antineoplastic agents - therapeutic use (9) 9
medicine & public health (9) 9
young adult (9) 9
chemotherapy (8) 8
everolimus (8) 8
analysis (7) 7
efficacy (7) 7
medical prognosis (7) 7
pharmacokinetics (7) 7
pharmacology & pharmacy (7) 7
prognosis (7) 7
retrospective studies (7) 7
treatment outcome (7) 7
antineoplastic agents - adverse effects (6) 6
antineoplastic agents - pharmacokinetics (6) 6
cancer therapies (6) 6
clinical trials (6) 6
gastroenterology and hepatology (6) 6
medicine, general & internal (6) 6
neoplasms - drug therapy (6) 6
patients (6) 6
research (6) 6
safety (6) 6
therapy (6) 6
adolescent (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
dosage and administration (5) 5
liver (5) 5
mammalian target (5) 5
medical research (5) 5
metastasis (5) 5
sorafenib (5) 5
surgery (5) 5
toxicity (5) 5
5-fluorouracil (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
capecitabine (4) 4
care and treatment (4) 4
cholangiocarcinoma (4) 4
diagnosis (4) 4
disease (4) 4
enets consensus guidelines (4) 4
expression (4) 4
fluorouracil - administration & dosage (4) 4
fluorouracil - adverse effects (4) 4
gemcitabine (4) 4
hepatectomy (4) 4
hilar cholangiocarcinoma (4) 4
intrahepatic cholangiocarcinoma (4) 4
medicine, experimental (4) 4
metabolism (4) 4
neoplasms (4) 4
netherlands (4) 4
pharmacology/toxicology (4) 4
prospective studies (4) 4
sirolimus - analogs & derivatives (4) 4
survival rate (4) 4
tor serine-threonine kinases - antagonists & inhibitors (4) 4
adjuvant treatment (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
biomarkers (3) 3
breast-cancer (3) 3
carcinoma (3) 3
carcinoma, hepatocellular - drug therapy (3) 3
carcinoma, hepatocellular - mortality (3) 3
complications and side effects (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
dihydrouracil dehydrogenase - metabolism (3) 3
diseases (3) 3
dose-response relationship, drug (3) 3
dpd deficiency (3) 3
drug therapy (3) 3
drugs (3) 3
fluorouracil (3) 3
growth-factor receptor (3) 3
guidelines (3) 3
hepatoma (3) 3
kaplan-meier estimate (3) 3
liver cancer (3) 3
liver neoplasms - drug therapy (3) 3
liver neoplasms - mortality (3) 3
maximum tolerated dose (3) 3
metastases (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 1, pp. 54 - 63
Journal Article
Acta oncologica (Stockholm, Sweden), ISSN 0284-186X, 2017, pp. 1 - 3
Journal Article
Journal of hepatology, ISSN 0168-8278, 08/2019
Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma (HCC). We aimed to compare the efficacy and safety of a combination... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e14020 - e14020
Journal Article
BMC cancer, ISSN 1471-2407, 2015, Volume 15, Issue 1, p. 564
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 8/2018, Volume 25, Issue 8, pp. 2467 - 2474
Journal Article
Virchows Archiv : an international journal of pathology, ISSN 0945-6317, 08/2019
In perihilar cholangiocarcinoma (PHC), interpretation of the resection specimen is challenging for pathologists and clinicians alike. Thorough and correct... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e14088 - e14088
Journal Article
Hepatology, ISSN 0270-9139, 03/2014, Volume 59, Issue 3, pp. 996 - 1006
Diagnosis of hepatocellular carcinoma (HCC) primarily involves imaging. The aim of this study was to assess the accuracy of 18 F‐fluorocholine ( 18 F‐FCH)... 
Journal Article
CardioVascular and Interventional Radiology, ISSN 0174-1551, 3/2019, Volume 42, Issue 3, pp. 484 - 484
Toward the end of the second paragraph in the Discussion section, there is a word missing in the sentence. 
Nuclear Medicine | Medicine & Public Health | Imaging / Radiology | Cardiology | Ultrasound | Hepatocellular carcinoma | Survival
Journal Article
The Oncologist, ISSN 1083-7159, 07/2018, Volume 23, Issue 7, pp. 766 - e90
经验总结 • 与依维莫司相比,BEZ235 治疗未显示出疗效增加,可能与耐受性较差相关。 • 晚期胰腺神经内分泌肿瘤患者中磷脂酰肌醇3‐激酶和哺乳动物雷帕霉素靶蛋白通路的双靶向假设可能需要使用其他药物进行进一步研究。 摘要 背景 .... 
THERAPY | ONCOLOGY | SAFETY | RESISTANCE | IDENTIFICATION | PI3K/MTOR INHIBITOR | PI3K/AKT/MTOR PATHWAY | Clinical Trial Results
Journal Article
The Oncologist, ISSN 1083-7159, 04/2018, Volume 23, Issue 4, pp. 399 - e33
经验总结 • 激励患者参加化学预防研究具有挑战性。 • 使用毒性药物进行化学预防不可行。 摘要 背景 . LKB1突变是导致Peutz‐Jeghers综合征(PJS)的潜在基因异常, 且是依维莫司的潜在靶标。在本项II期研究中, 考察了依维莫司对PJS患者息肉和肿瘤生长的疗效。 方法 .... 
RAPAMYCIN | AGENTS | ONCOLOGY | MTOR INHIBITORS | CANCER | Clinical Trial Results
Journal Article